Women often encountered the "broken rung" along their career journey. What is your experie
Kansas City chapter of the HealthCare Businesswoman's Association (HBA) held a roundtable discussion on overcoming one of the biggest...
Women often encountered the "broken rung" along their career journey. What is your experience?
Kansas City chapter of the HealthCare Businesswoman's Association (HBA) held a roundtable discussion on overcoming one of the biggest...
More I-O targets mean more shots on goal.
New report provides update on the fast moving, ever growing field of study in immuno-oncology. Full report in September Cancer Reviews...
New Report Available from ACS: Progress in Global Cancer Fight is not only Possible, but Achievable
"The Cancer Atlas, 3rd edition, a comprehensive global overview of cancer around the globe, concludes that progress in the fight against...
Breast Cancer Awareness Month begins today and I honor you!
As we begin Breast Cancer Awareness Month, I am reminded of all the incredible colleagues, researchers, advocates, patients, family and...
Great progress in cancer drug development and approvals but still incredible unmet need.
In the 1980s, only 4% of new drugs approved by the FDA were cancer treatments. But since 2010, cancer drugs have claimed 27% of new...
How long should an office visit be? Is 20 minutes enough? Can you call that patient-centric care?
This seems like a silly question. Of course it is not enough. But physicians today feel the pressure to see more and more patients,...
Cancer Medicines Value in Context: PhRMA Report May 2019 - A slide resource kit
PhRMA released its Cancer Medicines Value in Context slide deck. It is a rich cache of data and slides resources on the current cancer...
Top 20 Drugs of 2018 from Fierce Pharma
"Check out the list below, and you'll notice several major blockbusters benefiting from biosimilar delays. You'll also see some...
IQVIA report outlines key 2018 approvals and more
See summary below and click on image to see full IQVIA 2019 report. "There were 15 therapeutic oncology new active substances (NASs) and...
